The case of Genentech's breast cancer treatment T-DM1 demonstrates the challenges of balancing regulatory oversight with patients' desire to access experimental medications and drugmakers' business interests, the Boston Globe reports. Ensuring a drug is safe requires years of clinical trials and extensive evaluations by regulators and companies...
More...